The Efficacy of Rituximab plus Hyper-CVAD Regimen in Mantle Cell Lymphoma Is Independent of FCγRIIIa and FCγRIIa Polymorphisms

References

• Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999; 36 (2): 115–27.
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol. 1995; 6 (3): 257–62.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998; 16 (12): 3803–9.
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed man-tle-cell lymphoma and previously treated mantle-cell lym-phoma, immunocytoma, and small B-cell lymphocytic lym-phoma. J Clin Oncol. 2000; 18 (2): 317–24.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23 (28): 7013–23.
   PubMed Web of Science ®Google Scholar
• van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens. 2003; 61 (3): 189–202.
   PubMed Web of Science ®Google Scholar
• Clarkson SB, Kimberly RP, Valinsky JE, et al. Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med. 1986; 164 (2): 474–89.
   PubMed Web of Science ®Google Scholar
• Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCyRIIIA polymorphism on the concentration-effect relation-ship. Cancer Res. 2004; 64 (13): 4664-9.
   Google Scholar
• Parren PW, Warmerdam PA, Boeije LC, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest. 1992; 90 (4): 1537-46.
   Google Scholar
• Harjunpaa A, Junnikkala S, Meni S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000; 51 (6): 634-41.
   PubMed Web of Science ®Google Scholar
• van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006; 12 (13): 4027–35.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99 (3): 754–8.
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rit-uximab in patients with follicular lymphoma. J Clin Oncol. 2003; 21 (21): 3940–7.
   PubMed Web of Science ®Google Scholar
• van der Pol WL, Jansen MD, Sluiter WJ, et al. Evidence for non-random distribution of Fcgamma receptor genotype combinations. Immunogenetics. 2003; 55 (4): 240–6.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005; 23 (3): 474–81.
   PubMed Web of Science ®Google Scholar
• Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. FCyRIIIa and FCyRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 2004; 103 (4): 1472–4.
   PubMed Web of Science ®Google Scholar
• Lin TS, Flinn IW, Modali R, et al. FCyRIIIa and FCyRIIa polymorphisms may not correlate with response to alem-tuzumab in chronic lymphocytic leukemia. Blood. 2005; 105 (1): 289–91.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17 (4): 1244.
   Web of Science ®Google Scholar
• Galimberti S, Morabito F, Guerrini F, et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol. 2003; 120 (3): 405–12.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17 (12): 2257–317.
   PubMed Web of Science ®Google Scholar
• Kim DH, Jung HD, Kim JG, et al. FCyRIIIA gene poly-morphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006; 108 (8): 2720–5.
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal anti-body rituximab in vitro: CD55 and CD59 regulate comple-ment-mediated cell lysis. Blood. 2000; 95 (12): 3900–8
   PubMed Web of Science ®Google Scholar
• Belhadj K, Delfau-Larue MH, Elgnaoui T, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol. 2004; 15 (3): 504–10.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003; 102 (2): 749–55.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, et al. Long-term fol-low-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 200; 22 (8): 1460-8.
   Google Scholar